Stock Analysis
Stryker CorporationSYK
P/E 30.31×· 5Y range 27.75–55.89×· bottom 2% of history
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsStrong Buy34 analystsP/E 30.3× sits at the 2nd percentile of its 5.086926762491444-year history.
Cash covers 23% of debt · Q2 2026.
PMP Verdict
Strong business, attractive price
Strengths
- Quality90
- Financial Health87
High-quality business at an attractive price.
Bull Case
- ✓Altman Z 4.1 — safe-zone balance sheet
- ✓ROE 15.5% — efficient capital deployment
- ✓Revenue CAGR 10.1% — durable top-line growth
- ✓Interest coverage 10.3× — debt well covered
- ✓P/E 30.3× at bottom 2% of 5-year history
What's happening with SYK
Profile
Strong earnings quality, financial health and growth.
How is each axis scored?
- Valuation69/100 · Moderate
- P/E vs own history (2th pct)25/25
- FCF yield (4.2%)12/25
- P/S (4.4x)20/25
- EV/EBIT (22.6x)12/25
- Growth85/100 · Strong
- Revenue CAGR (10.1%)20/25
- Net income CAGR (13.0%)20/25
- EPS CAGR 5Y (12.6%)20/25
- Fwd implied growth (79.0%)25/25
- Profitability72/100 · Moderate
- ROIC (12.2%)12/25
- ROE (15.5%)20/25
- Net margin (14.4%)20/25
- Operating margin (21.4%)20/25
- Financial Health87/100 · Strong
- Altman Z (4.13)25/25
- Current ratio (2.16)25/25
- Interest coverage (10.3x)25/25
- Net cash / debt (D/A 25%)12/25
- Quality90/100 · Strong
- Piotroski F (6/9)15/25
- Beneish M (-2.63)25/25
- FCF conversion (126%)25/25
- Margin stability (σ 2.9%)25/25
- Moat68/100 · Moderate
- ROIC >12% years (2/10 yrs)0/25
- Median gross margin (64.0%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 8.2%)18/25
About Stryker Corporation
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. Show more
The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Headquarters: PORTAGE, MI · Employees: 56,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
69BP/E (TTM)30.3xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 27.7x–55.9x · 2nd pct
P/FCF23.7xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield4.2%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.9%–4.5% · 98th pct
P/S (TTM)4.38xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 4.0x–7.0x · 4th pct
EV/EBIT22.6xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 19.9x–47.0x · 2nd pct
EV/Sales4.8xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E16.9xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio4.72xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.62C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield1.18%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio35.3%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
72B+ROIC12.2%C
Grade C: AverageNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE15.5%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA7.9%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin14.4%A
Grade A: HighNet Income / Revenue
Operating Margin21.4%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin65.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin18.2%A
Grade A: HighFCF / Revenue
True FCF Margin17.2%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
85ARevenue CAGR10.1%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR13.0%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)12.6%C
Grade C: OkCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth79.0%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+0.4%B
Grade B: FlatShare count change over 5Y
SBC / Net Income6.7%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
87AAltman Z-Score4.13A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.16xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.08xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage10.3xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment2.5yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT2.2xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.64xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.23xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
90A+Piotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.63A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion126.1%A
Grade A: StrongFCF / Net Income
Margin Stability2.9%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue3.2%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.55xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Wells Preston Wendell Filed | Wells Preston Wendell | SellJ | -109 | |
Wells Preston Wendell Filed | Wells Preston Wendell | SellJ | -962 | |
Crotty Dylan Bram Filed | Crotty Dylan Bram | SellOpen market sale | -441 | |
STRYKER RONDA E Filed | STRYKER RONDA E | SellOpen market sale | -805 | |
STRYKER RONDA E Filed | STRYKER RONDA E | SellOpen market sale | -3852 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
STRYKER RONDA E Filed | STRYKER RONDA E | SellOpen market sale | -3274 | |
STRYKER RONDA E Filed | STRYKER RONDA E | SellOpen market sale | -16612 | |
STRYKER RONDA E Filed | STRYKER RONDA E | SellOpen market sale | -10812 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
68BROIC >12% Years2/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)64.0%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor8.2%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$9.72
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$9.09
Cash & short-term investments per share (Finnhub)
Book Value / Share$62.71
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$15.45B
Total debt obligations (short + long term)
Cash & Equiv.$3.48B
Cash and short-term investments
Net Debt$11.97B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$23.99B
Shareholders' equity (book value)
Asset / Liability2.00xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$113.15B
Current Market Capitalization
Beta0.79B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Stryker Corporation (SYK)
Piotroski F-Score of 6/9 indicates mixed fundamentals for Stryker Corporation. Altman Z-Score of 4.13 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.63 suggests a low likelihood of earnings manipulation.
- Stryker Corporation converts about 18% of revenue into free cash flow — strong cash generation.
- Takes ~2.5 years to repay net debt from free cash flow.
See how SYK ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all SYK moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 292.30 | +3.79% | 2.67 |
| Oct 15 | After-hours | 293.23 | +4.12% | 2.90 |
| Oct 6 | Regular | 277.35 | -2.76% | -2.00 |
Frequently Asked Questions about SYK
What is the current Stryker Corporation (SYK) stock price?
SYK is trading at $294.66 at the last market close, up 0.49% on the session. PreMarketPrice tracks SYK pre-market, intraday and after-hours prices.
Is SYK stock a buy right now?
PreMarketPrice's quantitative model rates Stryker Corporation's financial health at 87/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is SYK stock overvalued?
Stryker Corporation trades at a trailing P/E of 30.3 and our valuation score rates it 69/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Stryker Corporation report earnings?
No confirmed earnings date is currently scheduled for SYK. The Earnings section lists recent reports and updates as dates are announced.
What sector does Stryker Corporation operate in?
Stryker Corporation operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Stryker Corporation do?
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices.
About Stryker Corporation (SYK) Stock
Stryker Corporation (SYK) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Stryker Corporation is trading at $294.66, up 0.49% on the day with a market capitalization of $113.2 billion. The financial health score for SYK is 87/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for SYK stock.
SYK Stock Analysis & Key Metrics
On PreMarketPrice, you can track Stryker Corporation (SYK) across multiple dimensions:
- Pre-market price & movement: Real-time SYK stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for SYK with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Stryker Corporation across multiple reporting periods.
- Financial health score: A composite score of 87/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for SYK.
- Sector peers: Compare SYK against 6 other healthcare stocks on key financial metrics.
Is SYK a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Stryker Corporation (SYK) as an investment. The financial health score of 87/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Stryker Corporation (SYK) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.